Ambas entidades participan conjuntamente en el proyecto OVERCAD, cuyo objetivo es desarrollar una nueva estrategia terapéutica eficaz para el tratamiento de cáncer de ovario resistente, centrada en ...
Read moreThe Phase IIa study REIMAGINE evaluated the safety and preliminary efficacy of vafidemstat in agitation/aggression in borderline personality disorder (BPD), attention-deficit/hyperactivity disorder (A...
Read moreThe MYC oncogene is deregulated in approximately 70% of human cancers and is associated with aggressive disease and cancer drug resistance, making it one of the most sought-after targets in oncology. ...
Read morePeaches Biotech está investigando con su ensayo piloto, en fase I-II, del PRS® CK STORM contra la tormenta de citoquinas que se da en una cantidad significativa de casos en personas afectadas por vi...
Read moreADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors
Read moreOryzon Genomics, S.A, a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the fou...
Read moreLeading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD)
Read moreCTH120 is an investigational drug that modulates neuroplasticity, a property of the brain affected in many neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), Down...
Read moreStudy provides clinical scales and thresholds for patient selection in future clinical trials, based on aggressiveness, cognition, and behavioral traits
Read moreLa nueva compañía estará enfocada en las fases iniciales de desarrollo y validación preclínica de soluciones terapéuticas (CRO) dirigidas al área del metabolismo. Afrontará, según sus fundado...
Read moreTREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone, a novel, brain-penetrant and selective PPAR gamma agonist, to treat patients with Rett syndrome.
Read moreGENNIUS, developed by researchers from the University of Navarra and Stanford University, could revolutionize the process of finding new drugs.
Read more